Clinical trials: Coagulation Disorder, Blood
Hemophilia A, Hemophilia B
Validation and Reliability of the CHO-KLAT in Turkish
The aim of this study is to investigate the Turkish validity and reliability of the Canadian Haemophilia Outcomes-Kids' Life Assessment Tool version2.0.
- Trial name
- NCT05439642
- Testing
- Evaluation of health related quality of life
- Where
- 4 sites in Turkey (Türkiye)
- Volunteers
- 100 people
- Sponsor
- Yuzuncu Yil University
Extracorporeal Circulation, Inflammation
Rheoparin-coated Tubing System for Minimized Extracorporeal Circulation (MECC)
In this study, the investigators would like to compare a heparin-coated tubing system for minimized extracorporeal circulation (MECC) with the conventional tubing system for MECC, which does not contain heparin coating.
- Conditions
- Extracorporeal Circulation, Inflammation, Blood Coagulation, Intracranial Embolism
- Trial name
- RheoMECC (NCT02321917)
- Testing
- MECC system with rheoparin coating
- Where
- 2 sites in Switzerland
- Volunteers
- 50 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Hemophilia A
Individualizing Hemophilia Prophylaxis Using Thromboelastography
Currently dosing for prophylaxis is not individualized, and the general approach is to use a dose of 25-40 units/kg given 3 times per week or every other day.
- Trial name
- NCT02582060
- Testing
- Thromboelastography/Thromboelastometry-Guided Treatment Regimen
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Children's Hospital Los Angeles
Chediak-Higashi Syndrome
Study of Chediak-Higashi Syndrome
Chediak-Higashi syndrome (CHS) is a rare autosomal recessive disorder characterized in its classical form by oculocutaneous albinism, a bleeding diathesis, recurrent infection due to abnormal neutrophil and natural killer cell…
- Trial name
- NCT00005917
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- National Human Genome Research Institute (NHGRI)
Wiskott-Aldrich Syndrome
Long Term Safety Follow up of Haematopoietic Stem Cell Gene Therapy for the Wiskott Aldrich Syndrome
An open follow up study of patients enrolled in the Phase 1/2 clinical trial of haematopoietic stem cell gene therapy for the Wiskott-Aldrich Syndrome and treated with autologous CD34+ cells transduced with the w1.6_hWASP_WPRE…
- Trial name
- WASFUP (NCT02333760)
- Testing
- Autologous CD34+ cells transduced with WASP lentiviral vector
- Where
- 2 sites in France, United Kingdom
- Volunteers
- 10 people
- Sponsor
- Genethon
Sepsis, Blood Coagulation Disorders
Analysis of the Coagulopathy Developed by COVID-19 Infected Patients
Increased D-dimers at admission of COVID-19 infected patients entering hospital due to a severe disease is a risk factor for death.
- Conditions
- Sepsis, Blood Coagulation Disorders, Thrombin, Disseminated Intravascular Coagulation
- Trial name
- COVID-TGT (NCT04356950)
- Testing
- Thrombin generation test assay, Fibrin generation markers assays
- Where
- 4 sites in France
- Volunteers
- 175 people
- Sponsor
- Centre Hospitalier Universitaire de Nīmes
Thrombocytopenia Purpura, Chronic HBV Infection
to Evaluate the Efficacy and Safety of Eltrombopag for Immune Thrombocytopenia With Chronic HBV Infection
Primary Objective: To evaluate the efficacy of 6-week Eltrombopag to treat immune thrombocytopenia with chronic hepatitis B virus infection.
- Trial name
- NCT03664518
- Testing
- Eltrombopag
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Hemophilia
The Effectiveness of Recombinant Coagulation Factor IX With Recombinant Albumin (rIX-FP) in Severe Hemophilia B Patients
The pivotal clinical data support prolonged dosing intervals of up to 14 days for routine prophylaxis in hemophilia B patients. The majority of adult and pediatric patients using Idelvion for routine prophylaxis had a median…
- Trial name
- NCT04108260
- Testing
- Albutrepenonacog Alfa 1 UNT [IDELVION]
- Where
- Taiwan
- Volunteers
- 5 people
- Sponsor
- National Taiwan University Hospital
Hemophilia
Safety and Efficacy of FVIIa to Prevent Excessive Bleeding in Hemophilia Patients With Inhibitors Undergoing Major Surgery
This is an interventional, prospective, international, multicenter, single-arm, Phase 3, and sequential efficacy and safety study in adolescents and adults with congenital hemophilia A or B with inhibitors to factor VIII (FVIII)…
- Trial name
- SCOPE HIM (NCT05695391)
- Testing
- Coagulation Factor VIIa (Recombinant)
- Where
- 15 sites in United States, Malaysia and 4 more
- Volunteers
- 2 people
- Sponsor
- Laboratoire français de Fractionnement et de Biotechnologies
Immune Thrombocytopenia
Use of Vitamin D as An Adjuvant Treatment in Children With Chronic Idiopathic Thrombocytopenic Purpura
Immune thrombocytopenia is an autoimmune disease in which platelets are targeted by the host immune system. Platelet depletion occurs when autoantibodies targeting glycoproteins (αIIb-β3 and GPIb) found on the surface of…
- Trial name
- MansouraU (NCT06073925)
- Testing
- VIT D
- Volunteers
- 30 people
- Sponsor
- Mansoura University
Immune Thrombocytopenia (ITP), ITP - Immune Thrombocytopenia
A Study of Efgartigimod IV in Participants From 12 Years to Less Than 18 Years of Age With Chronic Immune Thrombocytopenia (ITP)
The main purpose of this study is to confirm the correct dose of efgartigimod IV for treating patients aged 12 to younger than 18 years with chronic immune thrombocytopenia (ITP).
- Conditions
- Immune Thrombocytopenia (ITP), ITP - Immune Thrombocytopenia, ITP, Immune Thrombocytopenic Purpura
- Trial name
- Advance Jr (NCT07194850)
- Testing
- Efgartigimod IV
- Where
- 26 sites in France, Germany and 8 more
- Volunteers
- 24 people
- Sponsor
- argenx
Immune Thrombocytopenic Purpura (ITP)
A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
Primary immune thrombocytopenia (ITP) is a condition where the immune system mistakenly destroys platelets, which are cells that help stop bleeding. This leads to a lower number of platelets, making it easier to bruise or bleed.
- Trial name
- NCT06948318
- Testing
- Mezagitamab
- Where
- 118 sites in United States, Australia and 13 more
- Volunteers
- 150 people
- Sponsor
- Takeda
Thrombosis, Hemorrhage
Pharmacogenomics of Warfarin in Hispanics and Latinos
Warfarin is a commonly used blood thinner to treat and prevent blood clots. It is important to take the right dose of warfarin because too much can increase the risk of bleeding and too little can increase the risk of blood…
- Trial name
- NCT02972385
- Testing
- Mouthwash sample, Blood Draw
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- University of Arizona
Hemophilia A
A Study of PEGylated Recombinant Factor VIII (BAX855) in Previously Untreated Young Children With Severe Hemophilia A
This study is for young children with severe hemophilia A who have previously not been treated with BAX855 or other FVIII concentrates. The main aim of the study is to check for side effects from treatment with BAX855.
- Trial name
- NCT02615691
- Testing
- PEGylated Recombinant Factor VIII, ITI
- Where
- 91 sites in United States, Austria and 21 more
- Volunteers
- 120 people
- Sponsor
- Baxalta now part of Shire
Immune Thrombocytopenia
Teriflunomide Plus High-dose Dexamethasone as First-line Treatment in Newly Diagnosed Primary Immune Thrombocytopenia
A randomized, open-label, multicenter study to compare the efficacy and safety of teriflunomide plus high-dose dexamethasone compared to high-dose dexamethasone monotherapy for the first-line treatment of adults with newly…
- Trial name
- NCT06176235
- Testing
- Teriflunomide, Dexamethasone
- Where
- 10 sites in China
- Sponsor
- Peking University People's Hospital
Fibrin Blood Clot, Infertility, Female
Ovarian Hyperstimulation and Fibrin Clot Properties.
The impact evaluation of ovarian hyperstimulation on coagulation and fibrinolysis in infertile women. Comparative analysis between different ovarian stimulation protocols on thrombin formation and efficiency of fibrinolysis in…
- Conditions
- Fibrin Blood Clot, Infertility, Female, Endometriosis
- Trial name
- NCT04166825
- Testing
- fibrin clot properties
- Where
- Poland
- Volunteers
- 300 people
- Sponsor
- Jagiellonian University
Acquired Thrombotic Thrombocytopenic Purpura
Improvement of Immunologic and Molecular Techniques for the Diagnosis and Follow-up of Patients With Thrombotic Thrombocytopenic Purpura
The lack of ADAMTS13 is the only biological marker that is specific for aTTP diagnosis8 and the assessment of ADAMTS13 is of clinical importance because it is essential for the rapid differential diagnosis between aTTP and other…
- Trial name
- NCT05046717
- Testing
- ADAMTS13 Activity Assays
- Where
- 6 sites in Portugal, Spain
- Volunteers
- 500 people
- Sponsor
- Fundación Española de Hematología y Hemoterapía
Chronic Myeloproliferative Disorders, Leukemia
Peripheral Stem Cell Transplant in Treating Patients With High-Risk Leukemia
RATIONALE: Giving chemotherapy and total-body irradiation before a donor peripheral stem cell transplant helps stop the growth of cancer and abnormal cells and helps stop the patient's immune system from rejecting the donor's…
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Myelodysplastic/Myeloproliferative Diseases
- Trial name
- NCT00066417
- Testing
- cyclophosphamide, cyclosporine, fludarabine phosphate
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Immune Thrombocytopenia
DEX Combined With RTX, CSA and IVIG in the Management of Newly Diagnosed ITP Patients
The project was undertaken by Qilu Hospital, Shandong University in China. In order to report the efficacy and safety of dexamethasone combined with rituximab, cyclosporin and intravenous immunoglobulin in the management of newly…
- Trial name
- NCT02834468
- Testing
- DEX Combined With RTX, CSA and IVIG
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Shandong University
Systemic Lupus Erythematosus, Inflammatory Myopathy
BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases
The objective of this study is to evaluate the efficacy and safety of BCMA/CD19 chimeric antigen receptor (CAR)-modified T cells in the treatment of autoimmune diseases.
- Conditions
- Systemic Lupus Erythematosus, Inflammatory Myopathy, Systemic Sclerosis (SSc), ANCA-associated Vasculitis
- Trial name
- NCT06794008
- Testing
- BCMA-CD19 CAR-T therapy
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Peking University People's Hospital